The U.S. FDA has granted Orphan Drug Designation for asedebart (Lu AG13909), Lundbeck's novel investigational anti-ACTH monoclonal antibody, for the treatment of endogenous Cushing's syndrome ...
Valby, Denmark, 11 September, 2026 - Lundbeck today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to asedebart (Lu AG13909), Lundbeck's novel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results